The Cancer Immunotherapy (CIMT) consortium is a non profit organisation and was founded in fall 2002 as an information and education platform for immunological cancer therapy. Physicians and researchers from different fields of clinical and theoretical medicine were the founding members of the association that operates as an independent non-profit organization. The purpose of CIMT is to promote the development of cancer immunotherapies by: * Establishing a communication platform in order to facilitate the communication between scientists of all faculties with interest in cancer immunotherapy. We improve knowledge exchange between industry based scientists, academic scientists, regulatory authorities and physicians alike. Our scientific meetings, educational symposia and publications serve this purpose. * Educating health-professionals through annual meetings, advanced education seminars and publication of textbooks. * Cooperating with partners in related consortia, regulatory agencies, journals, academic institutions and companies. * Initiating working parties that actively accelerate the development in the field.